Portugal's Cannabis Export Boom Is Hostage to One Licensing Queue

October 1, 2026

Photo by Bernd 📷 Dittrich via Unsplash.

Sixty-six thousand, three hundred and five kilograms. That's how much dried cannabis flower left Portugal between January and June 2026 -- a single half-year figure that already covers 83% of everything the country shipped out in all of 2025. If the second half of the year even roughly mirrors the first, Portugal is on track to nearly double its export volume again, continuing a run that has made it the default processing and re-export hub for medical cannabis flowing into Germany and, increasingly, the UK.

Here's the part that should give anyone watching this market pause: that growth happened despite Portugal's regulator, not because of it. For roughly 18 months, INFARMED -- the national health authority that licenses every cultivation, manufacturing, import-export, and wholesale cannabis operation in the country -- went quiet in a way the industry now just calls the blackout. During that stretch it suspended or delisted more than 30% of its licensed companies, let export certificate turnaround balloon past 70 days, and sat on 2025 export figures long enough that Germany's own regulator published Portuguese import data before INFARMED published its own export data.

Strip away the acronyms and what you're looking at is a single choke point. One government office, processing one licensing and certification queue, now effectively sets the volume ceiling for a meaningful slice of the EU's entire medical cannabis trade. Portugal wants to be Europe's processing hub -- the place where EU-GMP flower gets handled, packaged, and certified before crossing into Germany's booming medical market. But the biggest threat to that ambition isn't competition from Spain or Malta. It's Portugal's own paperwork.

The Numbers Behind the Surge

Portugal's cannabis exports have grown substantially in recent years, and H1 2026 figures (66,305 kg) suggest exports could exceed last year's total.

Start with the trend line, because it tells you how fast this market has actually been moving. Portugal exported 11,973 kg of cannabis in 2023. That climbed to 31,188 kg in 2024 -- already a substantial jump -- and then to 79,883 kg in 2025, a 156% increase year over year. Against that backdrop, 66,305 kg in just the first six months of 2026 isn't a surprising headline so much as the continuation of a curve that's been steepening for three straight years.

Germany absorbs most of it. Of that H1 2026 total, 37,442 kg went to Germany alone, with Spain a distant second at 11,386 kg and Denmark third at 8,968 kg. That concentration matters: Portugal's export story is, in large part, a Germany story. Germany's medical cannabis market expanded considerably after its 2024 reforms loosened prescribing rules, and demand has been pulling EU-GMP-certified product toward whichever jurisdiction can process and certify it fastest. For the last few years, that's been Portugal -- cheap-ish greenhouse cultivation, EU-GMP manufacturing capacity, and proximity to the rest of the European supply chain.

There's a telling wrinkle in how we even know Germany's 2025 number. Germany's own regulator, BfArM, recorded 55.1 tonnes imported from Portugal in 2025 -- and published that figure before INFARMED released its own 2025 export totals. That's not just an awkward optics problem. It means the market learned the shape of Portugal's single biggest trade relationship from the receiving country's paperwork before the exporting country's own regulator said a word. For an industry that runs on licensed, auditable supply chains, having the destination market out-report the origin market is a small but real signal about where the transparency gaps sit.

None of this growth required Portugal's regulatory apparatus to function smoothly. It required Germany to keep buying and Portuguese growers and processors to keep producing. The INFARMED bottleneck discussed in the sections below didn't stop the volume from growing -- it just made growing that volume harder, slower, and more expensive than it needed to be.

The Blackout: 18 Months of Silence and Revocations

Photo via Unsplash.

Industry people don't call it an investigation or a review. They call it the INFARMED blackout, and the name tells you something about how it felt from the outside: roughly 18 months, starting around mid-2025, of thin, inconsistent communication from the one agency every licensed cannabis company in Portugal depends on for certificates, renewals, and inspections.

The trigger was narrow. In June 2025, a media expose documented small amounts of illicit cannabis moving through a handful of legal channels -- a compliance failure, real but limited in scope. INFARMED's response was not limited in scope. Since January 2026, the regulator's own published lists show more than 30% of licensed companies either suspended or delisted entirely. Cultivation authorizations fell from 38 in 2025 to 27 by the middle of 2026. Total authorized entities across every category -- 24 manufacturing, 38 import-export, 15 wholesale-distribution -- dropped from 49 to 43.

Some of those revocations were high-profile. Cannacare lost its licence in March 2026, one of several companies to be struck off across late 2025 and into 2026. These weren't all fly-by-night operators; several had been operating under EU-GMP certification, the same compliance standard that's supposed to be the whole point of doing business in a regulated jurisdiction like Portugal rather than a grey-market one.

What this looks like, structurally, is a familiar regulatory pattern: a narrow scandal involving a small number of bad actors triggers a broad enforcement sweep that ends up catching compliant operators in the same net. It's the same shape as what happens after a bank fraud case triggers an industry-wide audit freeze, or a food safety scare triggers blanket recalls well beyond the contaminated batch. The intent -- tightening record-keeping and closing loopholes -- may well be defensible. The execution, stretched across 18 months with minimal public explanation, is what turned a compliance correction into something the industry started calling a blackout.

The practical effect was to shrink Portugal's licensed production and distribution base by roughly a third in under a year, right in the middle of its fastest export growth period on record. That's the contradiction sitting at the heart of this story: volume up, licensed capacity down, and one agency controlling both numbers.

Why One Queue Can Choke an Entire Industry

Photo via Pexels.

Here's where the abstract regulatory story turns into a cash-flow problem. At the worst point of the blackout, export certificates -- the paperwork that has to clear before product can legally leave Portugal for Germany or the UK -- were taking more than 70 days to issue, against a prior norm of around 30. That's not a rounding error. That's product sitting in warehouses, fully grown, fully processed to EU-GMP standard, waiting on a government stamp before it can generate a single euro of revenue.

Michael Sassano, CEO of a Portuguese cannabis pharmaceutical producer, said publicly what a lot of operators were saying privately: delays at this scale put Portugal's status as Europe's primary processing hub at real risk. That's not alarmist framing. Reports from top-tier companies in the space describe losing months of revenue to the certificate backlog -- for businesses running on the thin margins typical of EU-GMP cannabis production, where compliance costs are already high, a multi-month revenue gap is the kind of thing that forces layoffs, delayed harvests, or worse.

And this delay sits on top of an already slow baseline. Under Law 33/2018 and the decree-law governing Portuguese medical cannabis licensing, the process from initial application to issuance typically runs 6 to 12 months even when things are working normally. The export certificate backlog wasn't a new problem layered onto a fast system -- it was a new problem layered onto a system that was already one of the slower licensing pathways in the EU cannabis space.

The structural issue is that INFARMED is the only door. Cultivation, manufacturing, import-export, and wholesale-distribution licensing all run through one national agency, for an industry whose entire value proposition is export volume. There's no parallel path, no secondary regulator, no way to route around a bottleneck if that single agency slows down.

Canada offers a cautionary precedent here. After national legalization, Health Canada's licensing backlog for cultivation and processing applicants took years to clear, and the delay pushed meaningful investor capital toward other markets rather than waiting it out. Portugal's backlog is shorter in duration so far, but the mechanism is identical: when the only regulator in the room slows down, the market doesn't pause politely. It looks for somewhere else to go.

Signs of a Fix -- and Why the Transparency Fight Matters

Photo via Unsplash.

There's genuine evidence the worst of it has passed. At PTMC Lisbon on September 10, 2026, INFARMED's Vasco Bettencourt told the industry that export certificates are now issuing within 12 days -- down from the 70-plus-day peak. If that number holds up under continued volume growth, it's a real fix, not just a conference talking point.

Bettencourt's framing of the whole episode is worth taking seriously, because it changes how operators should interpret the crackdown. His position was that the enforcement action targeted record-keeping and traceability failures, not product safety or quality problems. That's a meaningful distinction. A crackdown on paperwork discipline is a different animal than a crackdown on contamination or diversion risk -- it suggests the underlying product and cultivation standards were never in question, only the documentation trail behind them.

Two concrete fixes were cited as having driven the turnaround. First, a quarterly reporting model, approved in June 2026, that puts INFARMED on a regular public disclosure cadence rather than an ad hoc one. Second, and more structurally important, is the MDS platform -- Portugal's national narcotics and psychotropic substances database, which had been previewed at PTMC as far back as 2025 and finally went into production in 2026. The MDS now handles import and export certificate issuance directly, which is presumably most of why 70 days became 12: a manual or semi-manual process got replaced with a database-driven one. INFARMED also says it has held more than 14 meetings with licensed companies since June, a level of direct engagement that was conspicuously absent during the blackout itself.

But the transparency fight that forced some of this into the open is its own story. In early August 2026, the opposition party Iniciativa Liberal pressed Portugal's Health Minister directly over the slowdown and the fact that 2025 export figures still hadn't been published. INFARMED released them on August 21 -- after Germany's BfArM had already published its own import numbers covering the same trade relationship. That sequencing matters. When a foreign regulator discloses a bilateral trade figure before the domestic regulator does, it tells you which side of that relationship has been playing defense on transparency, and which side has been operating normally all along.

What Happens Next: Three Scenarios

Photo by Mike Tyurin via Pexels.

Three plausible paths forward, and they're not mutually exclusive so much as points on a spectrum of how durable the fix turns out to be.

The bull case takes the 12-day certificate figure at face value and assumes the MDS platform keeps scaling without new bottlenecks emerging. If that holds, there's no obvious reason the 2023-2025 growth trend doesn't continue compounding -- Germany's demand isn't slowing down, and Portugal's processing infrastructure, EU-GMP certifications, and geographic position in the European supply chain are all still intact. Under this scenario, Portugal cements itself as the EU-GMP hub for Germany's expanding medical market, and the paperwork crisis becomes a one-time growing pain rather than a structural weakness.

The bear case starts from a different number: cultivation authorizations already fell from 38 to 27, and total licensed entities from 49 to 43. Faster certificates don't put those licences back. Even if every remaining operator in Portugal processes export paperwork in 12 days flat, there are fewer growers and processors left to supply the volume that's supposed to keep doubling. A 30%-plus reduction in licensed production capacity is the kind of damage that doesn't reverse just because the queue got faster -- it has to be rebuilt through new applications running on that same 6-to-12-month baseline timeline.

The middle case, and probably the most historically grounded one, is that Portugal stabilizes as a smaller, more tightly regulated hub -- fewer companies, each larger and better capitalized, producing most of the volume -- while some of the growth that would have gone to new Portuguese entrants instead flows to competitors like Spain, Denmark (increasingly positioning as EU-GMP producers rather than just destination markets), or Malta. This mirrors a pattern seen repeatedly in regulated industries: early uncertainty in one jurisdiction doesn't necessarily collapse it, but it does redirect the marginal new investment toward wherever the regulatory path looks clearer. Nothing here warrants a dated prediction -- just the shape of the pattern.

The variable nobody can answer yet is institutional. Portugal has no independent cannabis regulator and no legislative mandate requiring INFARMED to keep reporting quarterly or meeting with licensees regularly. Whether the current transparency improvements are a permanent practice or a response to political pressure that fades once Iniciativa Liberal moves on to other issues is genuinely unknown. Operators watching this space should track three concrete things: the next INFARMED licensed-company list update, whether cultivation authorizations climb back past 27, and whether Germany's full-year 2026 BfArM import figures from Portugal keep pace with H1's 37,442 kg.

A 12-day certificate turnaround is real progress, and it deserves to be treated as such -- it's the difference between product sitting idle for over two months and a business that can actually plan around its export pipeline. But speed isn't the same as capacity. The licence attrition that cut Portugal's cultivation authorizations from 38 to 27 and its total licensed entities from 49 to 43 didn't get undone by a faster database. Portugal's export capacity in late 2026 is concentrated in fewer, larger hands than it was in 2025, and that's a structural fact the growth curve doesn't erase.

The broader lesson here isn't really about Portugal specifically -- it's about what any EU jurisdiction chasing this trade should take from watching this unfold. Export volume growth is only as durable as the slowest licensing desk in the entire chain. Germany's demand didn't blink during the blackout; the only thing that moved was how much Portugal could legally get out the door and how fast. That's a single point of failure sitting underneath a trade relationship worth tens of millions of euros, and the fix shouldn't require an opposition party forcing a transparency fight in parliament. Public reporting obligations need to exist before a crisis, written into the regulatory mandate itself, not improvised afterward as a response to political pressure.

The number to watch isn't Bettencourt's conference remarks. It's whether Germany's full-year 2026 BfArM import data lines up with Portugal's own published figures, and whether INFARMED publishes on a schedule or waits again until someone else's regulator forces its hand. A gap between those two datasets, or another delayed self-report, would say a great deal more about where this is actually headed than anything said from a podium in Lisbon.